AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE Life Science Investing
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 Life Science Investing
Cleo Diagnostics Revolutionises Ovarian Cancer Screening with Early Detection Medical Device Investing
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis Life Science Investing
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome Life Science Investing
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data Life Science Investing
